How is VIP dosed and mixed for a nasal spray?

50 mcg of VIP (Vasoactive Intestinal Peptide) from a 1 mg vial mixed with 2 mL is 10 units on a U-100 syringe.

Every vial at a glance. Pick a cell to draw it on the syringe.

Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
Vial1 mL of water2 mL of water3 mL of water
1 mg1 mg/mL: 50 mcg is 5 units, 100 mcg is 10 units, 200 mcg is 20 units0.5 mg/mL: 50 mcg is 10 units, 100 mcg is 20 units, 200 mcg is 40 units0.333 mg/mL: 50 mcg is 15 units, 100 mcg is 30 units, 200 mcg is 60 units
2 mg2 mg/mL: 50 mcg is 2.5 units, 100 mcg is 5 units, 200 mcg is 10 units1 mg/mL: 50 mcg is 5 units, 100 mcg is 10 units, 200 mcg is 20 units0.667 mg/mL: 50 mcg is 7.5 units, 100 mcg is 15 units, 200 mcg is 30 units
5 mg5 mg/mL: 50 mcg is 1 unit, 100 mcg is 2 units, 200 mcg is 4 units2.5 mg/mL: 50 mcg is 2 units, 100 mcg is 4 units, 200 mcg is 8 units1.667 mg/mL: 50 mcg is 3 units, 100 mcg is 6 units, 200 mcg is 12 units

Jump to a vial 1 mg 2 mg 5 mg

The searches found no label for a nasal product and no human nasal dose, as a study that put VIP in the nose of 12 healthy volunteers measured nasal effects, not a dose; the NCT04536350 registry entry gave 67 µg of aviptadil nebulised three times a day for ten days to 83 enrolled people with COVID-19, and Invicorp, a product for erectile dysfunction in adult males, holds 25 micrograms of aviptadil and 2 mg of phentolamine per dose.1234

Mixing a vial: the arithmetic

50 mcg of VIP (Vasoactive Intestinal Peptide) from a 1 mg vial mixed with 2 mL is 10 units on a U-100 syringe.

No label or maker's leaflet found gives vial strengths or a mixing water for VIP powder, so the table shows sums, not a product. The doses in the table are sums only and come from no label or trial; the NCT04536350 inhaled trial gave 67 µg per nebulisation1, and the searches found no nasal dose.

50 mcg of VIP (Vasoactive Intestinal Peptide) from a 1 mg vial mixed with 2 mL is 10 units on a U-100 syringe.

Doses in labels and trials

The Welsh appraisal report describes Invicorp, the only authorised aviptadil product the searches found, as 25 micrograms of aviptadil with 2 mg of phentolamine given by intracavernous injection, licensed for erectile dysfunction in adult males.2 The Swedish SmPC says Invicorp is given by direct intracavernous injection, into the penis, with 25 mikrogram of aviptadil and 2 mg of phentolamine mesilate in one 0.35 ml ampoule.3 The Welsh report caps injection frequency at once daily or three times weekly.2

The trials below gave aviptadil or VIP inhaled, by nebuliser, or intravenously, and their units are not converted.15

TrialDose and schedulePeopleLength
NCT04536350 registry entry (nebulised, terminated)67 µg nebulised three times a day, versus 0.9% NaCl placebo183 enrolled people with COVID-19 at high risk for ARDSten days
Leuchte 2008, open inhaled study (pulmonary hypertension)One inhaled 100-microg dose of aviptadil during right-heart catheterisation520 patients with pulmonary hypertensionOne dose
TESICO trial (intravenous)12-hour daily infusion targeting 600, 1200 and 1800 pmol/kg on days 1, 2 and 3, versus placebo6461 adults hospitalised for COVID-19 with acute hypoxemic respiratory failure received any infusion (231 aviptadil, 230 placebo)three days
Youssef 2022 trial, NCT04311697 (intravenous)Three 12-hour infusions at 50, 100 and 150 pmol/kg/hr, or saline placebo7Aviptadil or saline placebo3 successive days
Domschke 1978 (intravenous VIP)0.6, 1.3 and 3.3 pmol/kg/min8four healthy volunteers30 minute periods
Holm-Bentzen 1981 (intravenous VIP)0.5, 0.9 and 2.7 micro/g/kg-h, on a background infusion of pentagastrin, 100 ng/kg-h9six healthy volunteers1 h per dose

In the Youssef 2022 trial, 203 of 213 screened participants consented to randomisation, and 196 people with COVID-19 respiratory failure were treated, 131 on aviptadil and 65 on placebo.7 An animal study in mice and rats tested a VIP nasal spray at 40 microg/ml and 200 microg/ml, which is not a human dose.10 No logged VIP vial or schedule was available to report.

Storage

The Swedish SmPC for Invicorp, a ready-made solution in an ampoule, gives a shelf life of 6 månader (months) and says to keep it in a refrigerator and not to freeze it.3 The searches of DailyMed, regulators and PubMed turned up no storage statement for VIP powder, before or after mixing.

Frequently asked questions

What side effects were reported with aviptadil?

In the TESICO trial, infusion reactions of any grade on days 0 to 2 occurred in 86.6% on aviptadil and 57.4% on placebo, with hypotension in 58.4% and 41.3% and diarrhea in 39.8% and 11.3%.6 In the Youssef 2022 trial of intravenous aviptadil, mild-to-moderate diarrhea occurred in 32.8% on aviptadil and 1.5% on placebo.7

Did the FDA authorise aviptadil?

A trade news report says the FDA declined emergency use authorisation for Zyesami in critical COVID-19.11

References

  1. ClinicalTrials.gov. NCT04536350: Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS. 2023. clinicaltrials.gov
  2. AWTTC (Wales). AWMSG SECRETARIAT ASSESSMENT REPORT. awttc.nhs.wales
  3. Swedish Medical Products Agency. PRODUKTRESUMÉ. docetp.mpa.se
  4. PubMed. Functional effects of phosphoramidon and captopril on exogenous neuropeptides in human nasal mucosa. 1995. pubmed.ncbi.nlm.nih.gov
  5. PubMed. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. 2008. pubmed.ncbi.nlm.nih.gov
  6. PMC. Intravenous Aviptadil and Remdesivir for Treatment of COVID-19-associated Hypoxemic Respiratory Failure: Randomized, Placebo-controlled Trials. 2023. pmc.ncbi.nlm.nih.gov
  7. PMC. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*. 2022. pmc.ncbi.nlm.nih.gov
  8. PubMed. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. 1978. pubmed.ncbi.nlm.nih.gov
  9. PubMed. Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. 1981. pubmed.ncbi.nlm.nih.gov
  10. PubMed. Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration. 2013. pubmed.ncbi.nlm.nih.gov
  11. Pharmafile. FDA decline Emergency Use Authorisation for ZYESAMI® in patients with critical COVID - Pharmafile. pharmafile.com